Efficacy and safety of TDF/FTC-containing, first-line HAART in clinical practice: 3-year data from the German outpatient cohort

le van Lunzen, J, Fätkenheuer, G, Lutz, T, Klauke, S, Mauss, S, Knechten, H, Braun, P, Gallo, L, Goldbach, J
Foilsithe 2010

Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors

le Wiesmann, F., Naeth, G., Sarrazin, C., Berger, A., Kaiser, R., Ehret, R., Knechten, H., Braun, P.
Foilsithe in Med Microbiol Immunol (2014)

Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort

le Koegl, C, Wolf, E, Hanhoff, N, Jessen, H, Schewe, K, Rausch, M, Goelz, J, Goetzenich, A, Knechten, H, Jaeger, H
Foilsithe 2009

Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment

le Wiesmann, F., Naeth, G., Berger, A., Hirsch, H. H., Regenass, S., Ross, R. S., Sarrazin, C., Wedemeyer, H., Knechten, H., Braun, P.
Foilsithe in Med Microbiol Immunol (2015)

The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naïve and pre-treated but protease inhibitor (PI)- naïve hiv-infe...

le Knechten, H, Stephan, C, Mosthaf, FA, Jaeger, H, Carganico, A, Lutz, T, Schewe, K, Mayr, C, Wolf, E, Wellmann, E, Tappe, A
Foilsithe 2011

Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients

le Stephan, C, Jaeger, H, Carganico, A, Knecht, G, Lutz, T, Mayr, C, Mosthaf, FA, Koeppe, S, Mueller, M, Wolf, E, Tappe, A, Wellmann, E, Knechten, H
Foilsithe 2010